Grignon D, Troster M
Prostate. 1985;7(2):195-202. doi: 10.1002/pros.2990070209.
Twenty-eight pretreatment and posttreatment biopsies from 11 cases of prostatic adenocarcinoma were stained for prostate-specific acid phosphatase (PAP), prostate-specific antigen (PSA), and keratin to determine the effect of hormonal (diethylstilbestrol) therapy on these immunological markers. Treatment intervals ranged from 2 to 63 months. All pretreatment tumors were strongly positive for PAP, and nine were strongly positive for PSA. Two were weakly positive for PSA, and all were negative for keratin. In five of the 11 posttreatment group cases, staining with both PAP and PSA was reduced. In three posttreatment cases, the malignant epithelium showed a squamoid appearance, and in these areas the keratin gave a positive reaction. These findings indicate that immunohistochemical staining with PAP and PSA may change in response to hormonal therapy. These alterations may lead to false-negative results when using these techniques to identify the primary tumor source of metastatic deposits of prostatic carcinoma.
对11例前列腺腺癌患者治疗前和治疗后的28份活检标本进行前列腺特异性酸性磷酸酶(PAP)、前列腺特异性抗原(PSA)和角蛋白染色,以确定激素(己烯雌酚)治疗对这些免疫标志物的影响。治疗间隔为2至63个月。所有治疗前肿瘤的PAP均呈强阳性,9例PSA呈强阳性。2例PSA弱阳性,所有病例角蛋白均为阴性。在11例治疗后组病例中,5例PAP和PSA染色均减弱。3例治疗后病例中,恶性上皮呈现鳞状外观,在这些区域角蛋白呈阳性反应。这些发现表明,PAP和PSA的免疫组化染色可能会因激素治疗而发生变化。当使用这些技术识别前列腺癌转移灶的原发肿瘤来源时,这些改变可能导致假阴性结果。